ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
14. März 2022 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
04. Januar 2022 08:30 ET
|
ARCA biopharma, Inc.
Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
02. Dezember 2021 08:30 ET
|
ARCA biopharma, Inc.
Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company...
ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th
09. November 2021 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
02. November 2021 16:15 ET
|
ARCA biopharma, Inc.
On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with...
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data
28. Oktober 2021 16:30 ET
|
ARCA biopharma, Inc.
Enrollment completion anticipated by year end 2021Topline data anticipated in first quarter of 2022 WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16. September 2021 08:30 ET
|
ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
16. August 2021 08:05 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
09. August 2021 08:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
04. August 2021 16:15 ET
|
ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...